Shares of BlackBerry Limited (NASDAQ:BBRY) [Trend Analysis] swings enthusiastically in regular trading session, it an advance of 1.20% to close at $7.20. While most of us had their hopes pinned on TCL Communication Technology Holdings (TCT) unveiling the much-awaited BlackBerry QWERTY smartphone at CES 2017, it appears they will have to wait a while longer. The company has reported that while Android smartphone will be previewed at CES, it will be launched at MWC next month.
TCT in a press release on Wednesday revealed that amongst the first smartphones it will launch this year is the “latest BlackBerry smartphone”, said to be focused on “security, productivity and reliability.” It went on to say the smartphone will be previewed at CES, which it indeed did, revealing that it’s codename is Mercury as we’ve been hearing all along.
The company also revealed that the spacebar has a fingerprint sensor built into the space bar, while the keyboard itself has capacitive touch capabilities for scrolling. It will also feature a USB Type-C port for charging and data transfers, and it will run Android Nougat. Moving forward to saw long-term intention, the experts calculate Return on Investment of -3.30%. The stock is going forward its fifty-two week low with 15.49% and lagging behind from its 52-week high price with -21.54%. BBRY last month stock price volatility remained 2.70%.
Prima Biomed Ltd. (NASDAQ:PBMD) [Trend Analysis] knocking active thrust in leading trading session, shares an advance of 2.81% to 2.54 with around 53711 shares have changed hands in this session. Prima BioMed Ltd (PBMD) declared that it has entered into a new collaboration contract with Japan’s CYTLIMIC, a recent spin off from NEC Corporation (NEC), to test a cancer peptide vaccine in combination with IMP321.
Prima’s Chief Medical Officer, Dr Frédéric Triebel, said: “When IMP321 is used as an adjuvant to a cancer vaccine to boost tumour-specific CD8 T cells, it is used at a very low dose to get a local effect at the vaccine injection site. The use of IMP321 as an adjuvant to a vaccine is therefore different from Prima’s other combination approaches where higher doses are used to boost Antigen Presenting Cells (APCs) in the whole body. It is very encouraging that CYTLIMIC has committed further resources to this exciting research, based on several positive published studies using IMP321 as an adjuvant to cancer vaccines.”
CYTLIMIC’s President and Chief Executive Officer, Dr Shun Doi, said: “I am pleased with the progress to enter into this collaboration with Prima BioMed, which follows the successful research collaboration among NEC Corporation, Yamaguchi University and Prima BioMed, to realize an innovative peptide vaccine for cancer immunotherapy.” The stock is going forward its fifty-two week low with 49.37% and lagging behind from its 52-week high price with -38.57%.
Similar, the positive performance for the quarter recorded as -16.74% and for the year was -36.67%, while the YTD performance remained at 5.56%. PBMD has Average True Range for 14 days of 0.28.